Zimmer Biomet Holdings, Inc.

ZBH Healthcare Medical Devices

Zimmer Biomet Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $8.2 billion, up 7.20% from fiscal 2024. In the quarter to June 2026, revenue grew 4.80%, EPS grew 33.8%, free cash flow grew 13.1% and total debt fell 1.23%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for five.

95.06 0.68 +0.72%
Market cap
$18.0B
P/E
23.0×
Fwd P/E
17.7×
Dividend yield
1.01%
F-score
6/9
Altman Z
2.38
Beneish M
−2.59
Dividend safety
72/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

24.26 25.19 23.36 20.85
P/S ratio
2.44 2.16 2.10 1.94
P/FCF ratio
19.29 16.53 17.49 15.96
P/Operating CF
46.60 34.41 49.06 36.95
P/B ratio
1.53 1.40 1.39 1.31
EV/Sales
3.29 3.00 2.93 2.78
EV/EBITDA
10.94 11.28 10.78 10.21
EV/FCF
26.04 22.96 24.48 22.78
Current Ratio
2.43 1.98 1.73 1.69
Net Debt/EBITDA
10.74 15.80 10.96 11.84
Debt/Equity
0.64 0.59 0.59 0.59
Earnings Yield
4.12% 3.97% 4.28% 4.80%
Free Cash Flow Yield
5.18% 6.05% 5.72% 6.26%
Free Cash Flow per Share
1.35 1.60 1.06 1.28
Book value per Share
64.44 64.17 65.03 65.73
Free Cash Flow
267.70 315.90 206.90 246.00
EV/EBIT
19.76 22.52 20.93 19.60
Other line items

Show all line items

Columns are period end dates